Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia

  • Navas-Acosta, Josgrey del Valle
  • Hernández-Sánchez, Alberto|||0000-0002-6601-3096
  • González, Teresa
  • Villaverde Ramiro, Ángela|||0000-0002-7337-7218
  • Santos, Sandra
  • Miguel, Cristina|||0000-0001-7359-7993
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Granada, Isabel|||0000-0002-4275-0104
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sánchez, Ricardo|||0000-0002-6383-0381
  • Such, Esperanza|||0000-0001-6892-403X
  • Barrena, Susana
  • Ciudad Pizarro, Juana
  • Dávila-Valls, Julio|||0000-0002-5185-2073
  • De las Heras, Natalia|||0000-0002-5188-5350
  • García-de Coca, Alfonso|||0000-0002-4942-060X
  • Labrador, Jorge|||0000-0002-3696-0287
  • Queizán, José Antonio
  • Martín, Sandra
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Benito, Rocío|||0000-0001-9781-4198
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
Adult B-cell acute lymphoblastic leukemia (B-ALL) is characterized by genetic heterogeneity and a high relapse rate, affecting over 40% of adults. However, the mechanisms leading to relapse in adults are poorly understood. Forty-four adult B-ALL patients were studied at both diagnosis and relapse by next-generation sequencing (NGS). Four main genetic pathways leading to relapse in adults were identified: IKZF1 genetic profile, RAS mutations and TP53 alterations in Ph-negative B-ALL and acquisition of ABL1 mutations in Ph-positive patients. The most frequently deleted gene at diagnosis was IKZF1 (52%), and 70% of these patients had IKZF1 profile. Notably, 88% of patients with IKZF1 at diagnosis retained this genetic profile at relapse. Conversely, the acquisition of RAS mutations or the expansion of subclones (normalized variant allele frequency < 25%) present from diagnosis were observed in 24% of Ph-negative patients at relapse. In addition, 24% of relapses in the Ph-negative cohort could potentially be driven by TP53 alterations. Of these cases, five presented from diagnosis, and four emerged at relapse, mostly as "double-hit" events involving both TP53 deletion and mutation. In Ph-positive B-ALL, the main genetic finding at relapse was the acquisition of ABL1 mutations (86%). Three clonal evolution patterns were identified: the persistent clone trajectory (25%), the expanding clone trajectory (11%) and the therapy-boosted trajectory (48%). Our results reveal the presence of preferential biological pathways leading to relapse in adult B-ALL. These findings underscore the need for personalized therapeutic strategies to improve clinical outcomes in adult patients with B-ALL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia

  • Quijada-Alamo, M.
  • Perez-Carretero, C.
  • Hernandez-Sanchez, M.
  • Rodriguez-Vicente, A.E.
  • Herrero, A.B.
  • Hernandez-Sanchez, J.M.
  • Martin-Izquierdo, M.
  • Santos-Minguez, S.
  • Del Rey, M.
  • Gonzalez, T.
  • Rubio-Martinez, A.
  • de Coca, A.G.
  • Davila-Valls, J.
  • Hernandez-Rivas, J.A.
  • Parker, H.
  • Strefford, J.C.
  • Benito, R.
  • Ordonez, J.L.
  • Hernandez-Rivas, J.M.
Background Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes to disease progression remains poorly understood. Specifically, the biological and clinical consequences of concurrent high-risk alterations such as del(11q)/ATM-mutations and del(17p)/TP53-mutations have not been established. Methods We integrated next-generation sequencing (NGS) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 techniques to characterize the in vitro and in vivo effects of concurrent monoallelic or biallelic ATM and/or TP53 alterations in CLL prognosis, clonal evolution, and therapy response. Results Targeted sequencing analysis of the co-occurrence of high-risk alterations in 271 CLLs revealed that biallelic inactivation of both ATM and TP53 was mutually exclusive, whereas monoallelic del(11q) and TP53 alterations significantly co-occurred in a subset of CLL patients with a highly adverse clinical outcome. We determined the biological effects of combined del(11q), ATM and/or TP53 mutations in CRISPR/Cas9-edited CLL cell lines. Our results showed that the combination of monoallelic del(11q) and TP53 mutations in CLL cells led to a clonal advantage in vitro and in in vivo clonal competition experiments, whereas CLL cells harboring biallelic ATM and TP53 loss failed to compete in in vivo xenotransplants. Furthermore, we demonstrated that CLL cell lines harboring del(11q) and TP53 mutations show only partial responses to B cell receptor signaling inhibitors, but may potentially benefit from ATR inhibition. Conclusions Our work highlights that combined monoallelic del(11q) and TP53 alterations coordinately contribute to clonal advantage and shorter overall survival in CLL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

  • Blanco, Gonzalo|||0000-0001-6557-3764
  • Puiggros, Anna|||0000-0001-9627-4978
  • Baliakas, Panagiotis|||0000-0002-5634-7156
  • Athanasiadou, Anastasia
  • García-Malo, MaDolores
  • Collado, Rosa|||0000-0002-8205-6192
  • Xochelli, Aliki
  • Rodríguez-Rivera, María
  • Ortega, Margarita
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Luño, Elisa
  • Vargas, MªTeresa
  • Grau Cat, Javier
  • Martínez-Laperche, Carolina
  • Valiente, Alberto
  • Cervera, José|||0000-0001-8252-1106
  • Anagnostopoulos, Achilles|||0000-0003-4384-9031
  • Gimeno, Eva|||0000-0002-3534-6189
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Stalika, Evangelia
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Ortuño, Francisco José|||0000-0003-4450-9346
  • Robles, Diego
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • Ivars, David
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Stamatopoulos, Kostas|||0000-0001-8529-640X
  • Espinet Solà, Blanca|||0000-0002-4294-8145
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53 abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53 abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53 abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

  • Puiggros, Anna|||0000-0001-9627-4978
  • Collado, Rosa|||0000-0002-8205-6192
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Ortega, Margarita
  • Ruiz-Xivillé, Neus
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Luño, Elisa
  • González, Teresa
  • Navarro, Blanca
  • García-Malo, MaDolores
  • Valiente, Alberto
  • Hernández, José Ángel
  • Ardanaz, María Teresa
  • Piñan, María Ángeles
  • Blanco, María Laura
  • Hernández-Sánchez, María|||0000-0001-9968-2782
  • Batlle Lopez, Ana|||0000-0003-4143-9020
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Salido, Marta|||0000-0001-9988-5977
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Gimeno, Eva|||0000-0002-3534-6189
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Terol, María José
  • Ortuño, Francisco José|||0000-0003-4450-9346
  • Costa, Dolors|||0000-0002-8276-3292
  • Moreno, Carol|||0000-0003-3275-0271
  • Carbonell, Félix
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Delgado, Julio|||0000-0002-5157-4376
  • Espinet i Solà, Blanca
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. In all, 99/1045 (9.5%) patients displayed a CK. Despite ATM and TP53 deletions were more common in CK (25% vs 7%; P < 0.001; 40% vs 5%; P < 0.001, respectively), only 44% (40/90) patients with TP53 deletions showed a CK. CK group showed a significant higher two-year cumulative incidence of treatment (48% vs 20%; P < 0.001), as well as a shorter overall survival (OS) (79 mo vs not reached; P < 0.001). When patients were categorized regarding CK and HR-FISH, those with both characteristics showed the worst median OS (52 mo) being clearly distinct from those non-CK and non-HR-FISH (median not reached), but no significant differences were detected between cases with only CK or HR-FISH. Both CK and TP53 deletion remained statistically significant in the multivariate analysis for OS. In conclusion, CK group is globally associated with advanced disease and poor prognostic markers. Further investigation in larger cohorts with CK lacking HR-FISH is needed to elucidate which mechanisms underlie the poor outcome of this subgroup.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Conde, M. Isabel Prieto
  • Llop, Marta
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Prieto Conde, M. Isabel
  • Llop, Marta
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Montesinos, Pau|||0000-0002-3275-5593
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that PTK2/FAK, PTK2B/PYK2, LYN or SRC could be new prognostic markers in IR-AML. We assessed PTK2, PTK2B, LYN and SRC gene expression in a cohort of 324 patients, adults up to the age of 70, classified in the IR-AML cytogenetic group. Univariate and multivariate analyses showed that PTK2B, LYN and PTK2 gene expression are independent prognostic factors in IR-AML patients. PTK2B and LYN identify a patient subgroup with good prognosis within the cohort with non-favorable FLT3/NPM1 combined mutations. In contrast, PTK2 identifies a patient subgroup with poor prognosis within the worst prognosis cohort who display non-favorable FLT3/NPM1 combined mutations and underexpression of PTK2B or LYN. The combined use of these markers can refine the highly heterogeneous intermediate-risk subgroup of AML patients, and allow the development of risk-adapted post-remission chemotherapy protocols to improve their response to treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, K.
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Dlouhy, Iván|||0000-0003-3066-4732
  • Jares, Pedro
  • Martín-García, David|||0000-0002-0289-5915
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Ordóñez, G.R.
  • Rovira, Jordi|||0000-0001-8737-5005
  • Clot, Guillem|||0000-0003-2588-7413
  • Royo, C.
  • Navarro, Alba|||0000-0002-4041-0974
  • González Farré, Blanca|||0000-0002-1796-7248
  • Vaghefi, A.
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Rubio-Perez, C.
  • Tamborero, David
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Gonzalez-Barca, E.
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Miyoshi, H.
  • Ohshima, K.
  • Miyawaki, K.
  • Kato, K.
  • Akashi, K.
  • Mozos, Ana|||0000-0002-3350-1827
  • Colomo, Luis|||0000-0001-5236-5085
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Valera, A.
  • Carrió, A.
  • Costa, Dolors|||0000-0002-8276-3292
  • Lopez-Bigas, N.
  • Schmitz, R.
  • Staudt, L.M.
  • Salaverria, I.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Campo, Elias|||0000-0001-9850-9793
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

  • Moreno, María José
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Novelli, Silvana|||0000-0001-8750-0195
  • Mozos, Ana|||0000-0002-3350-1827
  • Aragó, Marc|||0000-0002-9645-0131
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Pallarès, Victor|||0000-0002-9851-0345
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Blanco, Oscar
  • González-Díaz, Marcos
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The CXCR4/CXCL12 axis has been extensively associated with different types of cancer correlating with higher aggressiveness and metastasis. In diffuse large B-cell lymphoma (DLBCL), the expression of the chemokine receptor CXCR4 is involved in the dissemination of malignant B cells and is a marker of poor prognosis. CXCR7 is a chemokine receptor that binds to the same ligand as CXCR4 and regulates de CXCR4-CXCL12 axis. These findings together with the report of CXCR7 prognostic value in several tumor types, led us to evaluate the expression of CXCR7 in diffuse large B-cell lymphoma biopsies. Here, we describe that CXCR7 receptor is an independent prognostic factor that associates with good clinical outcome. Moreover, the expression of CXCR7 associates with increased survival in CXCR4 + but not in CXCR4- DLBCL patients. Thus, the combined immunohistochemical evaluation of both CXCR7 and CXCR4 expression in DLBCL biopsies may improve their prognostic value as single markers. Finally, we show that CXCR7 overexpression in vitro is able to diminish DLBCL cell survival and increase their sensitivity to antitumor drugs. Hence, further studies on the CXCR7 receptor may establish its role in DLBCL and the molecular mechanisms that modulate CXCR4 activity.